The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Abstract Background: Tacrolimus (Tac) is an immunosuppressive drug used to prevent post-
transplant (PT) organ rejection. Continuous Tac monitoring is necessary to adjust the dose …

Background. There is marked heterogeneity in blood concentrations of tacrolimus following
standard body-weight-based dosing. This is most apparent in black patients, who have a …

Objectives: The aims of this study were to develop a population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome …

Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0), but whether this …

Background CYP3A5 genetic polymorphisms contribute to marked interindividual
differences in the metabolism of and response to tacrolimus in humans. Objective This study …

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

Previously, we reported that, at 3 months after renal transplantation, individuals with
CYP3AP1 genotype CYP3AP1* 1 (linked to CYP3A5* 1 and strongly associated with …